Phase 1 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin Amyloid
Pablo García‐Pavía(Universidad Francisco de Vitoria), Thibaud Damy(Amyloidosis Foundation), Robert J. Frost(Bayer (Switzerland)), Erwan Donal, Fabian aus dem Siepen(Heidelberg University), Arnt V. Kristen(Heidelberg University), Jan Grimm(Memorial Sloan Kettering Cancer Center), Michele Mercuri(Inserm), Olivier Lairez(Hôpital Rangueil), Peter van der Meer(University Medical Center Groningen), Roger M. Nitsch(University of Zurich), Aubin Michalon(Light Chain Bioscience (Switzerland)), Christoph Höck(Inserm), Peter C. Kahr(Inserm)
Cited by 233
Related Papers
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
|European Heart Journal|2022|2.7k
2023 ESC Guidelines for the management of cardiomyopathies
|European Heart Journal|2023|2.3k
2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2023|2.2k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k